Cordycepin (3'-Deoxyadenosine) | Bacterial Inhibitor

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	73-03-0
Formula :	C₁₀H₁₃N₅O₃
M.W :	251.24
SMILES Code :	OC[C@@H]1C[C@H]([C@H](N2C=NC3=C2N=CN=C3N)O1)O
Synonyms :	3'-Deoxyadenosine; NSC 63984; 9(3DeoxyDribofuranosyl)adenine
InChI Key :	OFEZSBMBBKLLBJ-BAJZRUMYSA-N
Pubchem ID :	6303

GHS Pictogram:
Signal Word:	Danger
Hazard Statements:	H301-H315-H319-H335
Precautionary Statements:	P261-P264-P270-P271-P280-P301+P310-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362+P364-P403+P233-P405-P501
Class:	6.1
UN#:	2811
Packing Group:	Ⅲ

3T3-L1 preadipocytes	10 μM	24 h	Cordycepin significantly inhibited the differentiation of 3T3-L1 preadipocytes into adipocytes, reduced lipid accumulation, and increased the expression of brown adipocyte markers (e.g., UCP1, CIDEA, PGC1α, and FNDC5). These effects were substantially abolished in the presence of the AMPK inhibitor Compound C.	PMC6361849
Primary microglial cells	500 ng/mL	24 h	To evaluate the effect of cordycepin on primary microglial cell polarization and metabolic reprogramming. Results showed that cordycepin promoted primary microglial cell polarization towards M2-like phenotype and restored glycolysis and OXPHOS levels.	PMC11336950
BV2 cells	500 ng/mL	24 h	To evaluate the effect of cordycepin on LPS +Aβ-induced BV2 cell polarization and metabolic reprogramming. Results showed that cordycepin promoted BV2 cell polarization towards M2-like phenotype and restored glycolysis and OXPHOS levels.	PMC11336950
HaCaT cells	200 μM	3 days	Decreased levels of the senescence marker p16 and p21 proteins, reduced SASP and SA-β-gal activity	PMC6557849
Skin fibroblasts	200 μM	3 days	Reduced levels of the DNA damage response marker γ-H2AX, decreased levels of the senescence marker p16 and p21 proteins, reduced SASP and SA-β-gal activity	PMC6557849
Primary hepatocytes	50 μM and 100 μM	12 h	To validate the effects of cordycepin on lipid metabolism and inflammation in primary hepatocytes. Cordycepin reduced lipid accumulation and downregulated the expression of fatty acid synthesis genes (Fasn, Scd1, Accα, Srebp) and inflammatory genes (Il1b, Il6, Tnfα, Ccl5, Cxcl10).	PMC8457150
L02 cells	50 μM and 100 μM	12 h	To evaluate the effects of cordycepin on lipid accumulation and inflammation in hepatocytes under metabolic stress. Cordycepin significantly reduced lipid droplet accumulation, decreased intracellular triglyceride (TG) and total cholesterol (TC) levels, and downregulated the expression of fatty acid synthesis genes (Fasn, Scd1, Accα, Pparγ) and inflammatory genes (Il6, Tnfα, Ccl5, Cxcl10).	PMC8457150
Bone marrow-derived neutrophils	10 μg/mL	2 h	To evaluate the effect of cordycepin on neutrophil chemotaxis, results showed cordycepin did not directly affect neutrophil chemotaxis	PMC8207641
Human dermal fibroblasts	50 μM and 100 μM	24 h	To evaluate the inhibitory effect of cordycepin on UVB-induced MMP-1 and MMP-3 expressions. Results showed that cordycepin inhibited UVB-induced MMP-1 and MMP-3 expressions in a dose-dependent manner.	PMC2739894
ECA109 cells	73.82 μM	48 h	Cordycepin and cisplatin synergistically inhibited the proliferation of esophageal cancer cells	PMC7567864
K70 cells	69.27 μM	48 h	Cordycepin and cisplatin synergistically inhibited the proliferation of esophageal cancer cells	PMC7567864
K180 cells	66.84 μM	48 h	Cordycepin and cisplatin synergistically inhibited the proliferation of esophageal cancer cells	PMC7567864
HK cells	86.12 μM	48 h	Cordycepin and cisplatin synergistically inhibited the proliferation of esophageal cancer cells	PMC7567864

{[proInfo.proName]}

CAS No.: 73-03-0

{[proInfo.proName]}

CAS No.: 73-03-0

Alternative Products

Product Details of Cordycepin

Safety of Cordycepin

Related Pathways of Cordycepin

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

C57BL/6 male mice	High-fat diet-induced obesity model	Oral gavage	40 mg/kg	Once daily for 4 weeks	Cordycepin significantly inhibited high-fat diet-induced weight gain, reduced white adipose tissue (WAT) mass, and improved metabolic profiles and glucose tolerance. Additionally, cordycepin promoted WAT browning, increased energy expenditure, and enhanced cold tolerance. These effects were associated with AMPK activation.	PMC6361849
APP/PS1 mice	Alzheimer's disease model	Intragastric administration	10 mg/kg	Once daily for 4 weeks	To evaluate the effect of cordycepin on cognitive function and neuronal damage in APP/PS1 mice. Results showed that cordycepin improved learning and memory abilities and attenuated neuronal damage in APP/PS1 mice.	PMC11336950
Mice	High-fat diet (HFD)-induced nonalcoholic steatohepatitis (NASH) model	Not specified	100 mg/kg and 200 mg/kg	Daily administration for 8 weeks	To evaluate the effects of cordycepin on HFD-induced hepatic steatosis and inflammation. Cordycepin significantly reduced liver weight (LW) and liver weight/body weight ratio (LW/BW), decreased hepatic and serum lipid (TG and TC) levels, and improved hepatic steatosis and inflammation.	PMC8457150
Male C57BL/6 mice	Controlled cortical impact (CCI)-induced traumatic brain injury (TBI) model	Intraperitoneal injection	10 mg/kg	Twice daily for one week	To evaluate the long-term neuroprotective effects of cordycepin in TBI mice, results showed cordycepin improved neurological deficits, reduced neuronal tissue loss, and preserved white matter integrity	PMC8207641
Nude mice	Esophageal cancer xenograft model	Intraperitoneal injection	25 mg/kg	Every 4 days	Cordycepin and cisplatin synergistically inhibited the growth of esophageal cancer xenograft tumors	PMC7567864

NCT00667329	Lymphoma	Phase 1	Active, not recruiting	July 2019	United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00483067	Leukemia	Phase 2	Completed	-	United States, Texas ... More >> U.T.M.D. Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00412594	Leukemia	Phase 2	Recruiting	June 2019	United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Less <<
NCT00656812	Lymphoma of Mucosa-Associated ... More >>Lymphoid Tissue Less <<	Phase 2	Completed	-	Austria ... More >> Universitätsklinikum Graz Graz, Austria, A-8036 Universitaetsklinik Innsbruck/ Klinik für Innere Medizin Innsbruck, Austria, A-6020 Krankenhaus der Stadt Linz Linz, Austria, A-4020 Universitaetsklinik f. Innere Medizin III Salzburg, Austria, A-5020 AKH Wien / Universitaetsklinik fuer Innere Medizin I Vienna, Austria, A-1090 Less <<
NCT02157181	Hairy Cell Leukemia (HCL)	Phase 2	Completed	-	Germany ... More >> Community based hemato-oncology medical office Ansbach, Germany, 91522 Community based hemato-oncology medical office Aschaffenburg, Germany, 63739 Community based hemato-oncology medical office Celle, Germany, 29221 St.-Johannes-Hospital Dortmund, Germany, 44137 Städtische Kliniken Esslingen Esslingen, Germany, 73728 Universitätsklinik Frankfurt Frankfurt am Main, Germany, 60596 Universitätsklinik Freiburg Freiburg, Germany, 79106 Community based hemato-oncology medical office Fürth, Germany, 90766 University Clinic \| Med. Cinic IV Justus-Liebig-University Gießen, Germany, 3592 Wilhelm-Anton-Hospital Goch, Germany, 47574 Kath. Krankenhaus Hagen gem. GmbH Hagen, Germany, 58095 Community based hemato-oncology medical office Halle, Germany, 06108 Community based hemato-oncology medical office Hamburg, Germany, 21073 Meditinische Hochschule (MHH) Hannover, Germany, 30623 Community based hemato-oncology medical office Heidelberg, Germany, 69115 Marienhospital Herne/ Klinikum der Ruhr-Universität Bochum Herne, Germany, 44625 Community based hemato-oncology medical office Hilden, Germany, 40721 Community based hemato-oncology medical office Hildesheim, Germany, 31134 Klinikum Idar-Oberstein Idar-Oberstein, Germany, 55743 Community based hemato-oncology medical office Jena, Germany, 07743 Community based hemato-oncology medical office Kassel, Germany, 34125 Community based hemato-oncology medical office Kiel, Germany, 24105 Community based hemato-oncology medical office Koblenz, Germany, 56068 Community based hemato-oncology medical office Kronach, Germany, 96317 Community based hemato-oncology medical office Leer, Germany, 26789 Community based hemato-oncology medical office Leipzig, Germany, 04103 Städtische Kliniken Leverkusen, Germany, 51375 Community based hemato-oncology medical office Magdeburg, Germany, 39104 Community based hemato-oncology medical office Marburg, Germany, 35037 Klinik Schwäbisch Gmünd / Staufer Klinik Mutlangen, Germany, 73557 Community based hemato-oncology medical office München, Germany, 80335 Community based hemato-oncology medical office München, Germany, 81241 Klinikum Großhadern München, Germany, 81377 Community based hemato-oncology medical office Neunkirchen, Germany, 66538 Community based hemato-oncology medical office Neuwied, Germany, 56564 Community based hemato-oncology medical office Niddatal, Germany, 61194 Community based hemato-oncology medical office Nürnberg, Germany, 90449 MVZ Klinikum Osnabrück Osnabrück, Germany, 49076 Community based hemato-oncology medical office Pforzheim, Germany, 75179 Klinikum Ernst von Bergmann gGmbH Potsdam, Germany, 14467 St. Josefs-Krankenhaus Potsdam, Germany, 14471 Community based hemato-oncology medical office Schweinfurt, Germany, 97421 St. Marien-Krankenhaus Siegen, Germany, 57072 Community based hemato-oncology medical office Straubing, Germany, 94315 Diakonie-Klinikum Stuttgart Stuttgart, Germany, 70176 Community based hemato-oncology medical office Villingen, Germany, 78050 Community based hemato-oncology medical office Wolfsburg, Germany, 38440 Less <<
NCT00709215	Refractory TdT-Positive Leukem... More >>ia Less <<	Phase 1 Phase 2	Unknown	December 2010	United States, Massachusetts ... More >> Brigham & Women's Hospital Recruiting Boston, Massachusetts, United States, 02115 Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02115 Contact: Daniel J DeAngelo, MD, PhD. 617-632-2645 Daniel_Deangelo@dfci.harvard.edu Principal Investigator: Daneil J DeAngelo, MD, PhD. Sub-Investigator: Richard Stone, MD Sub-Investigator: L. Andres Sirulnik, MD Sub-Investigator: Martha Wadleigh, MD Sub-Investigator: Gregory Abel, MD, MPH Sub-Investigator: Susan L Buchanan, PA Sub-Investigator: Adriana Penicaud, PA Sub-Investigator: Ilene Galinsky, APRN Sub-Investigator: Eyal Attar, MD Sub-Investigator: Philip Amrein, MD Sub-Investigator: Karen Kuhn Ballen, MD United States, Texas Cancer Therapy Reasearch Center at UTHSCA Recruiting San Antonio, Texas, United States, 78229 Contact: Swaminathan Padmanabhan, MD 210-450-5094 PadmanabhanS@uthscsa.edu Sub-Investigator: Monica Mita, MD Principal Investigator: Alain Mita, MD Less <<
NCT00003005	Leukemia	Phase 1	Completed	-	United States, District of Col... More >>umbia Vincent T. Lombardi Cancer Research Center, Georgetown University Washington, District of Columbia, United States, 20007 United States, Maryland Johns Hopkins Oncology Center Baltimore, Maryland, United States, 21287 United States, Massachusetts New England Medical Center Hospital Boston, Massachusetts, United States, 02111 Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States, 02114 Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Boston Medical Center Boston, Massachusetts, United States, 02118 University of Massachusetts Memorial Medical Center Worcester, Massachusetts, United States, 01655 United States, Missouri Washington University Barnard Cancer Center Saint Louis, Missouri, United States, 63110 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 14263-0001 United States, North Carolina Lineberger Comprehensive Cancer Center, UNC Chapel Hill, North Carolina, United States, 27599-7295 United States, Ohio Arthur G. James Cancer Hospital - Ohio State University Columbus, Ohio, United States, 43210 United States, Oregon Oregon Cancer Center at Oregon Health Sciences University Portland, Oregon, United States, 97201-3098 Less <<

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed